Published in Hepatitis Weekly, September 5th, 2005
NexBio recently completed a preinvestigational new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA) and will submit an investigational new drug application (IND) to FDA and initiate human trials on Fludase shortly thereafter.
Fludase represents a first-in-class approach to fight influenza....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.